Janssen funds cancer study using VitalConnect, physIQ tech

VitalConnect and physIQ are teaming up with the Haga Teaching Hospital in the Netherlands to conduct a study on how wearable biosensors and artificial intelligence can augment care for cancer patients undergoing treatment. Specifically, the study — which is funded by Johnson& Johnson subsidiary Janssen Pharmaceuticals — is looking to see how the technology can detect adverse events in cancer treatment early on. 
Source: mobihealthnews - Category: Information Technology Source Type: news